NCT03938272View on ClinicalTrials.gov

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

PHASE3TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

July 14, 2021

Study Completion Date

July 14, 2021

Conditions
Hyperoxaluria, Primary
Interventions
BIOLOGICAL

Oxabact OC5 - Oxalobacter formigenes Strain HC-1

Live, commensal bacteria

Trial Locations (8)

1008

Charles Nicolle University Hospital, Tunis

3000

Hédi Chaker University Hospital, Sfax

4054

Sahloul University Hospital, Sousse

37232

Vanderbilt University Hospital, Nashville

53127

Kindernierenzentrum Bonn, Bonn

Unknown

Centre Hospitalier Universitaire de Liège, Liège

Hospital Vall d'Hebron, Barcelona

NW3 2QG

Royal Free Hospital, London

Sponsors

Lead Sponsor

OxThera
All Listed Sponsors
lead

OxThera

INDUSTRY

NCT03938272 - An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria | Biotech Hunter | Biotech Hunter